Core Viewpoint - The company reported a total revenue of 465 million yuan for the year 2025, marking a year-on-year increase of 12.43%, while the net profit attributable to the parent company decreased by 1.76% to 51.15 million yuan [1] Group 1: International Expansion - The company has deepened its overseas layout, achieving significant results in business development, with overseas revenue growing by over 40% year-on-year, now accounting for more than 30% of total revenue [1] - The high-end pressure monitoring radiofrequency ablation catheter has been commercialized in over 20 countries, and the cryoablation system has successfully obtained EU certification, with commercial applications in Germany, Turkey, and Greece [1] - The company actively participated in major international academic conferences, showcasing its "electric fire ice" comprehensive solution, which has gained widespread attention and recognition in the industry [1] Group 2: Domestic Business and Product Innovation - The company continues to focus on breakthroughs in high-end procedures and product innovation, with the usage of pressure monitoring radiofrequency ablation catheters increasing by over 70% year-on-year [2] - The company remains a leader in industry technology, with the approval of the PulseMagic TrueForce disposable pressure monitoring cardiac pulsed electric field ablation catheter, which is the first in China to feature a saline infusion function [2] - The collaboration with the affiliated company, Shangyang Medical, on the PulseMagic Spiral catheter is expected to create a complete product matrix in the pulsed ablation field, playing a key role in the iteration of cardiac electrophysiology technology and domestic replacement [2]

Core Viewpoint - The company reported a total revenue of 465 million yuan for the fiscal year 2025, marking a year-on-year increase of 12.43%, while the net profit attributable to the parent company decreased by 1.76% to 51.15 million yuan [1] Group 1: International Expansion - The company has deepened its overseas layout, achieving significant results with overseas revenue growing by over 40% year-on-year, now accounting for more than 30% of total revenue, validating the effectiveness of its international strategy [1] - The high-end pressure monitoring radiofrequency ablation catheter has been commercialized in over 20 countries, and the cryoablation system has successfully obtained EU certification, with commercial applications in Germany, Turkey, Greece, and other countries, receiving positive clinical feedback [1] - The company actively participated in major international academic conferences, showcasing its "electric fire ice" comprehensive solution through high-quality live surgeries and discussions, gaining widespread attention and recognition in the industry [1] Group 2: Domestic Business and Product Innovation - The company continues to focus on breakthroughs in high-end procedures and product innovation, with the volume of three-dimensional surgeries steadily increasing, and the usage of pressure monitoring radiofrequency ablation catheters rising by over 70% year-on-year [2] - The company remains a leader in industry technology, with its self-developed PulseMagic™ TrueForce® disposable pressure monitoring cardiac pulsed electric field ablation catheter approved for market launch in November 2025, becoming the first in China equipped with saline infusion functionality [2] - The collaboration with the affiliated company, Shangyang Medical, which previously received approval for the PulseMagic™ Spiral disposable magnetic electric positioning cardiac pulsed electric field ablation catheter, forms a strong synergy, establishing a complete product matrix in the field of pulsed ablation [2]

Group 1 - The core viewpoint of the article is that Lexin Medical is focusing on overseas markets for its business development in the next 1-2 years, aligning with its strategic direction and growth potential [2] - The company defines the second industry curve as related businesses that align with its strategic development direction and have greater growth potential [2] Group 2 - The company is currently positioning itself based on its strategic planning, indicating a clear focus on international expansion [2] - The response to investor inquiries highlights the company's commitment to its strategic goals and future business planning [2]

Group 1 - The core viewpoint of the article highlights the financial performance of Microelectronic Physiology, which reported an operating income of approximately 465 million yuan for the year 2025, representing a year-on-year increase of 12.43% [1] - The net profit attributable to shareholders of the listed company was 51.15 million yuan, showing a slight decrease of 1.76% compared to the previous year [1] - The basic earnings per share were reported at 0.1087 yuan, which is a decrease of 1.72% year-on-year [1] Group 2 - The article also mentions a significant development in the video generation technology sector, where a new Chinese video model is capable of producing 15-second videos for commercial delivery using just a few prompt words, leading to a surge in related film and television stocks [1]

Core Viewpoint - Microelectrophysiology (688351.SH) reported a total operating revenue of 465 million yuan for the year 2025, representing a year-on-year growth of 12.43%, while the net profit attributable to the parent company decreased by 1.76% to 51.15 million yuan [1] Financial Performance - The company achieved a net profit of 23.66 million yuan after deducting non-recurring gains and losses, a significant increase from 5.08 million yuan in 2024 [1] International Expansion - The company's overseas revenue grew by over 40% year-on-year, accounting for more than 30% of total revenue, indicating the effective implementation of its internationalization strategy [1] - High-end pressure monitoring radiofrequency ablation catheters have been commercialized in over 20 countries [1] - The cryoablation system received EU certification and is being commercially applied in countries such as Germany, Turkey, and Greece, with positive clinical feedback [1] Brand and Market Development - The company actively participated in major international academic conferences, showcasing its "electric fire ice" comprehensive solution through high-quality live surgeries and seminars, gaining widespread attention and recognition in the industry [1] - Future strategies include continuous product innovation, strengthening brand development, and expanding channel networks to enhance competitiveness in overseas markets [1]

微电生理发布业绩快报，2025年度实现营业总收入4.65亿元，同比增长12.43%；净利润5115.17万元， 同比下降1.76%。报告期内，公司海外布局持续深化，业务发展取得显著成果。2025年度，公司海外收 入同比增长超过40%，总收入占比已超过30%，有力验证了国际化战略的有效推进，凸显出公司在技 术、产品与服务方面的综合竞争优势。 ...

格隆汇2月11日丨爱博医疗(688050.SH)在投资者互动平台表示，公司暂无光模块相关布局与研究。 ...

Group 1 - The company, Aibo Medical (688050.SH), holds a significant market share and leading position in the ophthalmic surgery and myopia prevention market in China [1] - The vision care business is currently experiencing rapid growth and is accelerating its expansion into high comfort and functional consumer product markets [1] - The company expresses strong confidence in its future development and will continue to actively promote market expansion [1]

Group 1 - The company has a high market share and leading position in the ophthalmic surgery and myopia prevention market in China [1] - The vision care business is experiencing rapid growth and is accelerating its expansion into high comfort and functional consumer product markets [1] - The company is confident about its future development and will continue to actively promote market expansion [1]

格隆汇2月11日丨爱博医疗(688050.SH)在投资者互动平台表示，公司暂无光模块相关布局与研究。 ...